- Home
- IROQ vs CHRS Comparison
IROQ vs CHRS Comparison
Compare IROQ & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROQ
- CHRS
- Stock Information
- Founded
- IROQ 1883
- CHRS 2010
- Country
- IROQ United States
- CHRS United States
- Employees
- IROQ N/A
- CHRS N/A
- Industry
- IROQ Savings Institutions
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IROQ Finance
- CHRS Health Care
- Exchange
- IROQ Nasdaq
- CHRS Nasdaq
- Market Cap
- IROQ 75.0M
- CHRS 84.2M
- IPO Year
- IROQ 2011
- CHRS 2014
- Fundamental
- Price
- IROQ N/A
- CHRS $0.82
- Analyst Decision
- IROQ
- CHRS Buy
- Analyst Count
- IROQ 0
- CHRS 3
- Target Price
- IROQ N/A
- CHRS $4.68
- AVG Volume (30 Days)
- IROQ 1.6K
- CHRS 1.3M
- Earning Date
- IROQ 08-28-2025
- CHRS 08-07-2025
- Dividend Yield
- IROQ 1.63%
- CHRS N/A
- EPS Growth
- IROQ 69.23
- CHRS N/A
- EPS
- IROQ 1.05
- CHRS N/A
- Revenue
- IROQ $25,099,000.00
- CHRS $272,251,000.00
- Revenue This Year
- IROQ N/A
- CHRS N/A
- Revenue Next Year
- IROQ N/A
- CHRS $106.56
- P/E Ratio
- IROQ $23.43
- CHRS $1.87
- Revenue Growth
- IROQ 12.02
- CHRS 19.87
- 52 Week Low
- IROQ $16.34
- CHRS $0.66
- 52 Week High
- IROQ $25.76
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- IROQ 51.14
- CHRS 53.13
- Support Level
- IROQ $24.35
- CHRS $0.72
- Resistance Level
- IROQ $24.98
- CHRS $0.77
- Average True Range (ATR)
- IROQ 0.28
- CHRS 0.04
- MACD
- IROQ -0.02
- CHRS 0.01
- Stochastic Oscillator
- IROQ 74.30
- CHRS 91.62
About IROQ IF Bancorp Inc.
IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.